Actuate Therapeutics, Inc. has announced its intention to offer and sell shares of its common stock in an underwritten public offering.
The Company plans to use the net proceeds for working capital and general corporate purposes.
Lucid Capital Markets is the sole book-running manager for the offering.
Proposed Public Offering
Actuate Therapeutics intends to offer and sell shares of its common stock in an underwritten public offering.
Use of Proceeds
The net proceeds from the offering will be utilized for working capital and general corporate purposes.
Book-Running Manager
Lucid Capital Markets is acting as the sole book-running manager for the offering.
- The offering is subject to market conditions, with uncertainties on completion and final terms.
- The Company's focus on developing therapies for difficult-to-treat cancers is highlighted through the proposed offering.
The announcement of the proposed public offering signifies Actuate Therapeutics' strategic move to raise capital for further development in cancer therapies.